<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocrinol Metab (Seoul)</journal-id><journal-id journal-id-type="iso-abbrev">Endocrinol Metab (Seoul)</journal-id><journal-id journal-id-type="publisher-id">ENM</journal-id><journal-title-group><journal-title>Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2093-596X</issn><issn pub-type="epub">2093-5978</issn><publisher><publisher-name>Korean Endocrine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26754586</article-id><article-id pub-id-type="pmc">4803547</article-id><article-id pub-id-type="doi">10.3803/EnM.2016.31.1.120</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="subheading"><subject>Clinical Study</subject></subj-group></subj-group></article-categories><title-group><article-title>Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA<sub>2</sub> in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Hyo-Sun</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Chang Hee</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sung Rae</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>Hak Chul</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-9415-9965</contrib-id><name><surname>Park</surname><given-names>Cheol-Young</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><collab>PROPIT Study Team</collab></contrib></contrib-group><aff id="A1"><label>1</label>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff><aff id="A2"><label>2</label>Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</aff><aff id="A3"><label>3</label>Department of Endocrinology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</aff><aff id="A4"><label>4</label>Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</aff><author-notes><corresp>Corresponding author: Cheol-Young Park. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. Tel: +82-2-2001-1869, Fax: +82-2-2001-1588, <email>cydoctor@chol.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2016</year></pub-date><volume>31</volume><issue>1</issue><fpage>120</fpage><lpage>126</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>03</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Korean Endocrine Society</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA<sub>2</sub> levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study.</p></sec><sec><title>Methods</title><p>We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA<sub>2</sub> for 48 weeks.</p></sec><sec><title>Results</title><p>Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (<italic>P</italic>&#x02264;0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA<sub>2</sub> was not significant after intervention in either group after treatment with pitavastatin for 1 year.</p></sec><sec><title>Conclusion</title><p>Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA<sub>2</sub> levels.</p></sec></abstract><kwd-group><kwd>Apolipoprotein B-48</kwd><kwd>Lp-PLA<sub>2</sub></kwd><kwd>Metabolic syndrome</kwd><kwd>Pitavastatin</kwd></kwd-group><funding-group><award-group><funding-source country="KR"><institution-wrap><institution>JW Pharmaceutical</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>With an increasing prevalence worldwide, metabolic syndrome (MS) has become a leading health concern [<xref rid="B1" ref-type="bibr">1</xref>]. MS is associated with a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality [<xref rid="B2" ref-type="bibr">2</xref>]. Dyslipidemia is one diagnostic criteria for the MS and these lipid abnormalities are recognized risk factors for cardiovascular disease (CVD) [<xref rid="B3" ref-type="bibr">3</xref>]. Statins decrease significant CVD risk in patients with MS by reducing low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and possibly by decreasing inflammation [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Apolipoprotein B (ApoB) is the main structural surface protein found on all &#x003b2; lipoproteins and is known to cause atherosclerosis [<xref rid="B5" ref-type="bibr">5</xref>]. Of two type of ApoB, ApoB-48 is an intestinally derived lipid with a chylomicron remnant that increases in postprandial hyperlipidemia, a known risk factor of coronary artery disease (CAD) [<xref rid="B6" ref-type="bibr">6</xref>]. The effect of statins on hepatic ApoB-100 is well known [<xref rid="B7" ref-type="bibr">7</xref>], but the direct effect of statins on intestinal ApoB-48 is less well understood.</p><p>Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>), an emerging biomarker of cardiovascular risk, is an inflammatory enzyme expressed in macrophages of atherosclerotic plaques and carried in the circulation predominantly bound to LDL-C [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>]. Recently, analysis of data from 32 prospective studies linked LP-PLA<sub>2</sub> activity directly with the risk of CVD [<xref rid="B10" ref-type="bibr">10</xref>]. Previous studies report that increased Lp-PLA<sub>2</sub> activity is associated with MS and incident fatal and non-fatal CVD [<xref rid="B11" ref-type="bibr">11</xref>]. High Lp-PLA<sub>2</sub> activity is observed in subjects with the MS and associated with several lipid-related risk factors such as ApoB [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Therefore, the purpose of the present study was to evaluate the effect of pitavastatin and life style modification (LSM) treatment on ApoB-48 and Lp-PLA<sub>2</sub> levels in subjects with MS, using serum samples from the PROPIT (PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome) trial.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Trial design</title><p>The PROPIT trial was a 12-month, multicenter, prospective, randomized open label study at 10 clinical centers in Korea. The detailed protocol for PROPIT has been previously described [<xref rid="B13" ref-type="bibr">13</xref>]. Briefly, after screening, selected subjects with MS were randomized into two groups: the pitavastatin (2 mg daily)+intensive LSM group or the intensive LSM only group. Subjects with LDL &#x02265;190 mg/dL or glycated hemoglobin (HbA1c) &#x02265;8% at the 24-week (6-month) follow-up visit were withdrawn from the study because there was a drug-na&#x000ef;ve arm in our study design. All subjects were trained for LSM with the same protocol at the time of enrollment by health professionals.</p></sec><sec><title>Study subjects</title><p>Between February 2008 and December 2010, 164 MS patients were enrolled in the PROPIT study. Among them, we randomly selected 37 and 38 subjects for the pitavastatin and LSM groups, respectively, after matching for age, sex, and body mass index.</p><p>Eligible patients were men and women aged 18 to 75 years with central obesity (waist circumference: men &#x02265;90 cm, women &#x02265;85 cm, according to guideline of the Korean Society for the Study of Obesity) [<xref rid="B14" ref-type="bibr">14</xref>] and impaired fasting glucose (fasting glucose &#x02265;100 mg/dL), which are essential components of MS, and one or more of the followings components: (1) TG &#x02265;150 mg/dL; (2) high density lipoprotein (HDL) for men &#x02264;40 mg/dL, and for women &#x02264;50 mg/dL; and (3) systolic blood pressure &#x02265;130 mm Hg or diastolic blood pressure (DBP) &#x02265;85 mm Hg. Selected subjects had no prior history of atherosclerosis or CVD. They were statin na&#x000ef;ve, with no prior use of oral hypoglycemic agents.</p><p>The exclusion criteria were the use of statins within the preceding 3 months; uncontrolled hypertension (DBP &#x02265;95 mm Hg); poorly controlled diabetes (HbA1c &#x02265;8.0%); high cholesterolaemia (LDL &#x02265;190 mg/dL or TG &#x02265;400 mg/dL); a past medical history of coronary disease, atherosclerosis, malignancy or severe infective disease; renal dysfunction (creatinine &#x02265;2.0 mg/dL) or hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase &#x02265;upper normal limit [UNL] &#x000d7;2.5); uncontrolled hypothyroidism (thyroid-stimulating hormone &#x02265;UNL &#x000d7;1.5); creatine phosphokinase &#x02265;UNL &#x000d7;2; pregnancy or possible pregnancy; and lactation.</p></sec><sec><title>Measurement of plasma levels of ApoB-48 and Lp-PLA2</title><p>Plasma concentration of ApoB-48 was measured by enzyme-linked immunosorbent assay (ELISA) kit (product code: SEB883Hu) which is a sandwich enzyme immunoassay for <italic>in vitro</italic> quantitative measurement of ApoB-48 in human serum, plasma, and other biological fluids. The plasma concentration of Lp-PLA<sub>2</sub> was determined by a commercially available Lp-PLA<sub>2</sub> ELISA kit (Uscn Life Science Inc., Houston, TX, USA).</p></sec><sec><title>Endpoint assessment</title><p>The primary end-point was the change from baseline in plasma level of ApoB-48 and Lp-PLA<sub>2</sub> after the 12-month intervention. Secondary end-points included changes from baseline in lipid profiles (TG, HDL, non-HDL, and LDL), ApoB-100/A1 ratio and high molecular weight (HMW) adiponectin.</p></sec><sec><title>Statistical analysis</title><p>The data are presented as mean&#x000b1;standard deviation for continuous variables and as proportions (%) for categorical variables. Baseline clinical and biochemical characteristics between the two treatment groups were compared using two-sample <italic>t</italic> test for continuous variables and chi-square test for categorical variables. The changes of the primary end-point and other parameters from baseline within groups were analyzed using a paired <italic>t</italic> test, and the significance of the changes between the treatment groups were analyzed using a two-sample <italic>t</italic> test. In a separate analysis, changes from baseline in the levels of ApoB-48 and LpPLA<sub>2</sub> according to their baseline values (i.e., below and above median values) were compared using a Wilcoxon signed rank test, and differences in changes between the treatment groups was analyzed using a Mann Whitney <italic>U</italic> test. All statistical analyses were carried out with SPSS version 21.0 (IBM Co., Armonk, NY, USA). A two-tailed <italic>P</italic>&#x0003c;0.05 was regarded as statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Baseline patient characteristics</title><p>All subjects were patients with MS, obesity and prediabetes, and all were statin na&#x000ef;ve, with no prior use of oral hypoglycemic agents. The two groups of patients were well-matched according to lipid profile, blood glucose level and the pattern of life style including the frequency of exercise, alcohol consumption and smoking. The mean body mass index and fasting plasma glucose level were around 27 kg/m<sup>2</sup> and 115 mg/dL, respectively. The number of subjects with coronary heart disease family history, insulin resistance (homeostasis model assessment of insulin resistance), and inflammation state (high-sensitivity C-reactive protein) did not differ between groups. Baseline characteristics of the study subjects are summarized in <xref ref-type="table" rid="T1">Table 1</xref>.</p></sec><sec><title>Changes in metabolic parameters, apolipoprotein, and Lp-PLA<sub>2</sub> in both groups after 12 months of treatment</title><p>After the 12 months of treatment, LDL-C and non-HDL cholesterol (HDL-C) were significantly reduced in the pitavastatin +LSM group compared with those in the LSM only group (<xref ref-type="table" rid="T2">Table 2</xref>). TG level was significantly lower in the pitavastatin +LSM group but slightly higher in LSM only group, but the differences were not significant (TG change: -24.7&#x000b1;54.1 mg/dL vs. 2.7&#x000b1;98.1 mg/dL, <italic>P</italic>=0.143).</p><p>The ApoB-100/A1 ratio was also significantly lower in both groups, but was much greater in the pitavastatin+LSM group (ApoB-100/A1 ratio change: -0.21&#x000b1;0.16 vs. -0.05&#x000b1;0.12, <italic>P</italic>&#x0003c;0.001).</p><p>HMW adiponectin increased in both groups, but there was no significant difference between the two groups. We evaluated the change of Lp-PLA<sub>2</sub> and ApoB-48 levels before and after intervention. Pitavastatin+LSM did not significantly affect ApoB-48 levels in subjects overall, but when we evaluated changes from baseline in ApoB-48 level according to baseline values (i.e., below and above median values), pitavastatin+LSM significantly reduced ApoB-48 levels in the group with above median baseline value of ApoB-48. There was no effect of pitavastatin+LSM on Lp-PLA<sub>2</sub> in either group (<xref ref-type="table" rid="T3">Table 3</xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We conducted a sub-analysis of the PROPIT study to evaluate the effect of combined therapy with a statin and LSM on lipid profiles, ApoB-48 and Lp-PLA<sub>2</sub> in MS patients. In our study, pitavastatin treatment significantly improved lipid profiles and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA<sub>2</sub> levels.</p><p>Insulin resistance is a major component of MS and represents major complications associated with atherogenic dyslipidemia [<xref rid="B15" ref-type="bibr">15</xref>]. Atherogenic dyslipidemia in MS patients is characterized by low HDL-C and high TG levels. TGs are associated with TG-rich lipoproteins (TRLs), and chylomicron remnants have been implicated as significant risk factors for atherosclerosis [<xref rid="B6" ref-type="bibr">6</xref><xref rid="B16" ref-type="bibr">16</xref>]. The small intestine regulates lipid metabolism in fed and fasting states and plays a central role in lipid homeostasis [<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">18</xref>]. Since the small intestine consists of insulin sensitive tissue, lipid synthesis pathways in the small intestine are also influenced by insulin resistance. ApoB-48 is present only in intestinally derived lipoproteins such as chylomicron and chylomicron remnants. High ApoB-48 levels suggest delayed metabolism of TRLs, which are commonly associated with insulin resistance and abdominal obesity [<xref rid="B19" ref-type="bibr">19</xref>]. In our study showed that pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48.</p><p>Some previous studies report that plasma level of ApoB-48 could be a marker of new onset as well as chronic CAD [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. Therapeutically, statins are most commonly used to reduce dyslipidemia via inhibition of endogenous hepatic cholesterol synthesis (inhibition of 3-hydroxy-3-methylglutaryl CoA reductase). Because the effect of statins on the intestine is relatively unknown, some other investigators have examined the effect of statins on levels of ApoB-48. Dane-Stewart et al. [<xref rid="B22" ref-type="bibr">22</xref>] reported that 80 mg/day of atorvastatin significantly lowered ApoB-48 levels in 10 normolipidemic patients with CAD. Lamon-Fava et al. [<xref rid="B23" ref-type="bibr">23</xref>] also documented that atorvastatin at both 20 and 80 mg/day significantly lowered ApoB-48 in the fed state in nine patients with combined hyperlipidemia.</p><p>There were some differences between our study and prior studies. Previously, the effect of statins on ApoB-48 was measured in the post-prandial setting by meal challenge test, because ApoB-48 reflects TG-rich remnant lipoproteins which are risk factors for CVD and increase in postprandial hyperlipidemia. In our study, we measured ApoB-48 in the fasting condition, and so the change of ApoB-48 level after intervention was lower than in prior studies. However, some studies report that a high fasting serum concentration of ApoB-48 also may be a risk factor for CAD [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B24" ref-type="bibr">24</xref>]. Although the change of ApoB-48 in the fasting state was smaller than in the fed state, we thought that it was important to measure ApoB-48 in the fasting state.</p><p>Lp-PLA<sub>2</sub>, also known as low density associated platelet-activating factor acetylhydrolase, is released from the macrophages of atherosclerotic plaques into circulation [<xref rid="B25" ref-type="bibr">25</xref>]. Lp-PLA<sub>2</sub> hydrolyzes oxidized phospholipids on LDL to lysophosphatidylcholine and oxidizes fatty acids, and lysophosphatidylcholine activates several second messengers with potentially atherogenic effects [<xref rid="B26" ref-type="bibr">26</xref>]. Several investigations report that Lp-PLA<sub>2</sub> is a cardiovascular risk marker independent of, and in addition to, traditional risk factors [<xref rid="B27" ref-type="bibr">27</xref><xref rid="B28" ref-type="bibr">28</xref>]. As an important predictor of CVD, Lp-PLA<sub>2</sub> has received attention as a potential new therapeutic target. The advent of some novel pharmacological inhibitors of this enzyme such as darapladib and varespladib may help to reduce the risk of CAD [<xref rid="B29" ref-type="bibr">29</xref>]. A previous study revealed that darapladib, when added to statins, prevents necrotic core expansion and offers great benefit in the reduction of plaque formation [<xref rid="B30" ref-type="bibr">30</xref>]. Some researchers have investigated the effect of statins on Lp-PLA<sub>2</sub> activity. Winkler et al. [<xref rid="B31" ref-type="bibr">31</xref>] reported that 80 mg/day of fluvastatin for 8 weeks decreased the activity of Lp-PLA<sub>2</sub> by 22.8% in subjects with type 2 diabetes. Schaefer et al. [<xref rid="B32" ref-type="bibr">32</xref>] also reported that 40 mg/day of atorvastatin reduced mean Lp-PLA<sub>2</sub> values by 26% over 36 weeks in 84 patients who had coronary heart disease and LDL-C levels &#x0003e;130 mg/dL. In contrast to previous studies, pitavastatin (2 mg/day) treatment did not reduce Lp-PLA<sub>2</sub> levels in our study.</p><p>There were several differences between our study and previous studies in Lp-PLA<sub>2</sub> as well. Previous studies evaluated the effect of statins on Lp-PLA<sub>2</sub> activity in subjects at high risk for CVD due to previous coronary disease or diabetes mellitus. However, this study excluded subjects at high risk for CVD (uncontrolled hypertension [DBP &#x02265;95], poorly controlled diabetes [HbA1c &#x02265;8.0%], or high cholesterolemia [LDL &#x02265;190 mg/dL or TG &#x02265;400 mg/dL]). Possibly because we focused on patients at relatively low risk for CVD, the effect of pitavastatin on the change of Lp-PLA<sub>2</sub> was lower than in previous studies. Another difference compared to other studies was the dosage of statin. Pitavastatin 2 mg shows similar effects to atorvastatin 10 mg in improving lipid profiles [<xref rid="B33" ref-type="bibr">33</xref>]. Prior studies investigating the effect of statins on the level of Lp-PLA<sub>2</sub> used a higher dosage of statin sufficient to reduce the level of Lp-PLA<sub>2</sub>. We thought that the dosage of pitavastatin in present study was not enough to change the levels of Lp-PLA<sub>2</sub>. In addition, we measured the mass concentration of Lp-PLA<sub>2</sub> by commercial assay. The median value of Lp-PLA<sub>2</sub> has varied widely in prior epidemiologic studies, making it difficult to use this assay for clinical purposes. It has been suggested that a measure of Lp-PLA<sub>2</sub> activity might serve as a more reproducible and representative biomarker of enzyme functions [<xref rid="B34" ref-type="bibr">34</xref>]. If we measured Lp-PLA<sub>2</sub> activity with Lp-PLA<sub>2</sub> mass concentration, we would have more accurate results for the effect of pitavastatin on Lp-PLA<sub>2</sub>.</p><p>Some important limitations of this study deserve mention. First, it was a sub-study with a relatively small number of subjects. Accordingly, the plasma levels of ApoB-48 and Lp-PLA<sub>2</sub> had wide standard deviations and statistical power was reduced. The strength of this study was that it is the first interventional study that investigated the effect of pitavastatin on the level of ApoB-48 and Lp-PLA<sub>2</sub>.</p><p>In conclusion, pitavastatin+LSM in MS patients at relatively low risk for CVD significantly reduced ApoB-48 levels in the higher baseline mean value group of ApoB-48, but did not significantly alter Lp-PLA<sub>2</sub> levels. Further studies with modified dosage and larger populations are needed to evaluate the effects of pitavastatin treatment on Lp-PLA<sub>2</sub> and ApoB-48.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank other investigators for their cooperation in this study. The full list of other investigators for this study is as follows: PROPIT Study Team Sung Hee Choi (Seoul National University Bundang Hospital, Seongnam, Korea), Soo Lim (Seoul National University Bundang Hospital, Seongnam, Korea), Ji A Seo (Korea University Ansan Hospital, Ansan, Korea), Jung Hyun Noh (Inje University Ilsan Paik Hospital, Goyang, Korea), Ji Oh Mok (Soonchunhyang University Bucheon Hospital, Bucheon, Korea), Ki Young Lee (Gachon University Gil Medical Center, Incheon, Korea), Jong Sook Park (Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea), Dae Jung Kim (Ajou University Hospital, Suwon, Korea), and Chang Beom Lee (Hanyang University Guri Hospital, Guri, Korea).</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICTS OF INTEREST:</bold> This study was supported by JW Pharmaceutical, Seoul, Republic of Korea. The sponsor participated in the study design, data collection and analysis of the data, but not in writing the manuscript and the decision to submit the manuscript for publication.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galassi</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group><article-title>Metabolic syndrome and risk of cardiovascular disease: a meta-analysis</article-title><source>Am J Med</source><year>2006</year><volume>119</volume><fpage>812</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">17000207</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottillo</surname><given-names>S</given-names></name><name><surname>Filion</surname><given-names>KB</given-names></name><name><surname>Genest</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Pilote</surname><given-names>L</given-names></name><name><surname>Poirier</surname><given-names>P</given-names></name><etal/></person-group><article-title>The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><fpage>1113</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">20863953</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>MA</given-names></name><name><surname>Rodriguez</surname><given-names>BL</given-names></name><name><surname>McKnight</surname><given-names>B</given-names></name><name><surname>McNeely</surname><given-names>MJ</given-names></name><name><surname>Edwards</surname><given-names>KL</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men</article-title><source>Am J Cardiol</source><year>2000</year><volume>86</volume><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">10946034</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundbye</surname><given-names>JB</given-names></name><name><surname>Thompson</surname><given-names>PD</given-names></name></person-group><article-title>Statin use in the metabolic syndrome</article-title><source>Curr Atheroscler Rep</source><year>2005</year><volume>7</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15683597</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQueen</surname><given-names>MJ</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Sniderman</surname><given-names>A</given-names></name><name><surname>Probstfield</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">18640459</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kugiyama</surname><given-names>K</given-names></name></person-group><article-title>Triglycerides and remnant particles as risk factors for coronary artery disease</article-title><source>Curr Atheroscler Rep</source><year>2006</year><volume>8</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">16510044</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Barrett</surname><given-names>PH</given-names></name><name><surname>O'Neill</surname><given-names>FH</given-names></name><name><surname>Thompson</surname><given-names>GR</given-names></name></person-group><article-title>Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome</article-title><source>Int J Obes Relat Metab Disord</source><year>2003</year><volume>27</volume><fpage>862</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">12821974</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolodgie</surname><given-names>FD</given-names></name><name><surname>Burke</surname><given-names>AP</given-names></name><name><surname>Skorija</surname><given-names>KS</given-names></name><name><surname>Ladich</surname><given-names>E</given-names></name><name><surname>Kutys</surname><given-names>R</given-names></name><name><surname>Makuria</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>2523</fpage><lpage>2529</lpage><pub-id pub-id-type="pmid">16960105</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stafforini</surname><given-names>DM</given-names></name><name><surname>Tjoelker</surname><given-names>LW</given-names></name><name><surname>McCormick</surname><given-names>SP</given-names></name><name><surname>Vaitkus</surname><given-names>D</given-names></name><name><surname>McIntyre</surname><given-names>TM</given-names></name><name><surname>Gray</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>7018</fpage><lpage>7024</lpage><pub-id pub-id-type="pmid">10066756</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><collab>Lp-PLA(2) Studies Collaboration</collab><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Orfei</surname><given-names>L</given-names></name><name><surname>Watson</surname><given-names>S</given-names></name><name><surname>Di Angelantonio</surname><given-names>E</given-names></name></person-group><article-title>Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>1536</fpage><lpage>1544</lpage><pub-id pub-id-type="pmid">20435228</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsimikas</surname><given-names>S</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Knoflach</surname><given-names>M</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name><name><surname>Egger</surname><given-names>G</given-names></name><name><surname>Notdurfter</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lipoprotein-associated phospholipase A<sub>2</sub> activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">19019993</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschler</surname><given-names>V</given-names></name><name><surname>Merono</surname><given-names>T</given-names></name><name><surname>Maccallini</surname><given-names>G</given-names></name><name><surname>Gomez Rosso</surname><given-names>L</given-names></name><name><surname>Aranda</surname><given-names>C</given-names></name><name><surname>Brites</surname><given-names>F</given-names></name></person-group><article-title>Association of lipoprotein-associated phospholipase A<sub>2</sub> activity with components of the metabolic syndrome in apparently healthy boys</article-title><source>Cardiovasc Hematol Agents Med Chem</source><year>2011</year><volume>9</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">21476960</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>ES</given-names></name><name><surname>Seo</surname><given-names>JA</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Noh</surname><given-names>JH</given-names></name><etal/></person-group><article-title>PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome</article-title><source>Clin Endocrinol (Oxf)</source><year>2015</year><volume>82</volume><fpage>670</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">25109606</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Song</surname><given-names>YD</given-names></name><name><surname>Kim</surname><given-names>HD</given-names></name><etal/></person-group><article-title>Cut-off value of waist circumference for metabolic syndrome patients in Korean adult population</article-title><source>J Korean Soc Study Obes</source><year>2004</year><volume>13</volume><fpage>53</fpage><lpage>60</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Natali</surname><given-names>A</given-names></name><name><surname>Bell</surname><given-names>P</given-names></name><name><surname>Cavallo-Perin</surname><given-names>P</given-names></name><name><surname>Lalic</surname><given-names>N</given-names></name><name><surname>Mingrone</surname><given-names>G</given-names></name></person-group><article-title>Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR)</article-title><source>J Clin Invest</source><year>1997</year><volume>100</volume><fpage>1166</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">9303923</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><name><surname>Bittner</surname><given-names>V</given-names></name><name><surname>Criqui</surname><given-names>MH</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name><etal/></person-group><article-title>Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association</article-title><source>Circulation</source><year>2011</year><volume>123</volume><fpage>2292</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">21502576</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haidari</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>N</given-names></name><name><surname>Mahbub</surname><given-names>F</given-names></name><name><surname>Uffelman</surname><given-names>KD</given-names></name><name><surname>Kohen-Avramoglu</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>31646</fpage><lpage>31655</lpage><pub-id pub-id-type="pmid">12070142</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vine</surname><given-names>DF</given-names></name><name><surname>Takechi</surname><given-names>R</given-names></name><name><surname>Russell</surname><given-names>JC</given-names></name><name><surname>Proctor</surname><given-names>SD</given-names></name></person-group><article-title>Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome</article-title><source>Atherosclerosis</source><year>2007</year><volume>190</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">16624317</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>I</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Ishimoto</surname><given-names>A</given-names></name><name><surname>Katsura</surname><given-names>S</given-names></name><name><surname>Toyokawa</surname><given-names>A</given-names></name><name><surname>Hayashi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Significance of measuring serum concentrations of remnant lipoproteins and apolipoprotein B-48 in fasting period</article-title><source>J Atheroscler Thromb</source><year>2009</year><volume>16</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">19262003</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Monguchi</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease</article-title><source>Clin Chim Acta</source><year>2013</year><volume>421</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">23428589</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varbo</surname><given-names>A</given-names></name><name><surname>Benn</surname><given-names>M</given-names></name><name><surname>Tybj&#x000e6;rg-Hansen</surname><given-names>A</given-names></name><name><surname>Jorgensen</surname><given-names>AB</given-names></name><name><surname>Frikke-Schmidt</surname><given-names>R</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group><article-title>Remnant cholesterol as a causal risk factor for ischemic heart disease</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>61</volume><fpage>427</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">23265341</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dane-Stewart</surname><given-names>CA</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Pal</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease</article-title><source>Metabolism</source><year>2003</year><volume>52</volume><fpage>1279</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">14564679</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamon-Fava</surname><given-names>S</given-names></name><name><surname>Diffenderfer</surname><given-names>MR</given-names></name><name><surname>Barrett</surname><given-names>PH</given-names></name><name><surname>Buchsbaum</surname><given-names>A</given-names></name><name><surname>Matthan</surname><given-names>NR</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism</article-title><source>J Lipid Res</source><year>2007</year><volume>48</volume><fpage>1746</fpage><lpage>1753</lpage><pub-id pub-id-type="pmid">17526934</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otokozawa</surname><given-names>S</given-names></name><name><surname>Ai</surname><given-names>M</given-names></name><name><surname>Diffenderfer</surname><given-names>MR</given-names></name><name><surname>Asztalos</surname><given-names>BF</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Lamon-Fava</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects</article-title><source>Metabolism</source><year>2009</year><volume>58</volume><fpage>1536</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">19592048</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racherla</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name></person-group><article-title>Utility of Lp-PLA<sub>2</sub> in lipid-lowering therapy</article-title><source>Am J Ther</source><year>2012</year><volume>19</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">20634673</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilensky</surname><given-names>RL</given-names></name><name><surname>Macphee</surname><given-names>CH</given-names></name></person-group><article-title>Lipoprotein-associated phospholipase A(2) and atherosclerosis</article-title><source>Curr Opin Lipidol</source><year>2009</year><volume>20</volume><fpage>415</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">19667981</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packard</surname><given-names>CJ</given-names></name><name><surname>O'Reilly</surname><given-names>DS</given-names></name><name><surname>Caslake</surname><given-names>MJ</given-names></name><name><surname>McMahon</surname><given-names>AD</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>Cooney</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lipoprotein-associated phospholipase A<sub>2</sub> as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1148</fpage><lpage>1155</lpage><pub-id pub-id-type="pmid">11036120</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>K</given-names></name><name><surname>Winkelmann</surname><given-names>BR</given-names></name><name><surname>Scharnagl</surname><given-names>H</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>Grawitz</surname><given-names>AB</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">15710755</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Garcia</surname><given-names>HM</given-names></name><name><surname>Serruys</surname><given-names>PW</given-names></name></person-group><article-title>Phospholipase A<sub>2</sub> inhibitors</article-title><source>Curr Opin Lipidol</source><year>2009</year><volume>20</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">19550325</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suckling</surname><given-names>KE</given-names></name></person-group><article-title>Phospholipase A<sub>2</sub> inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic</article-title><source>Expert Opin Investig Drugs</source><year>2009</year><volume>18</volume><fpage>1425</fpage><lpage>1430</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>K</given-names></name><name><surname>Abletshauser</surname><given-names>C</given-names></name><name><surname>Friedrich</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>Wieland</surname><given-names>H</given-names></name><name><surname>Marz</surname><given-names>W</given-names></name></person-group><article-title>Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>1153</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">15001601</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>EJ</given-names></name><name><surname>McNamara</surname><given-names>JR</given-names></name><name><surname>Asztalos</surname><given-names>BF</given-names></name><name><surname>Tayler</surname><given-names>T</given-names></name><name><surname>Daly</surname><given-names>JA</given-names></name><name><surname>Gleason</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A<sub>2</sub> in patients with coronary heart disease versus control subjects</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><fpage>1025</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">15842965</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokote</surname><given-names>K</given-names></name><name><surname>Bujo</surname><given-names>H</given-names></name><name><surname>Hanaoka</surname><given-names>H</given-names></name><name><surname>Shinomiya</surname><given-names>M</given-names></name><name><surname>Mikami</surname><given-names>K</given-names></name><name><surname>Miyashita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)</article-title><source>Atherosclerosis</source><year>2008</year><volume>201</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">18472103</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Lambeau</surname><given-names>G</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name></person-group><article-title>Lipoprotein-associated and secreted phospholipases A<sub>2</sub> in cardiovascular disease: roles as biological effectors and biomarkers</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>2183</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">21098459</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline Characteristics of Subjects in the Sub-Analysis</title></caption><alternatives><graphic xlink:href="enm-31-120-i001"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Variable</th><th valign="middle" align="center" rowspan="1" colspan="1">Pitavastatin+LSM (<italic>n</italic>=37)</th><th valign="middle" align="center" rowspan="1" colspan="1">Only LSM (<italic>n</italic>=38)</th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, yr</td><td valign="top" align="center" rowspan="1" colspan="1">52.9&#x000b1;8.5</td><td valign="top" align="center" rowspan="1" colspan="1">52.0&#x000b1;9.1</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male sex</td><td valign="top" align="center" rowspan="1" colspan="1">22 (59.5)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (65.8)</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">26.8&#x000b1;2.2</td><td valign="top" align="center" rowspan="1" colspan="1">27.1&#x000b1;3.6</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WC, cm</td><td valign="top" align="center" rowspan="1" colspan="1">91.8&#x000b1;4.4</td><td valign="top" align="center" rowspan="1" colspan="1">94.3&#x000b1;6.5</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SBP, mm Hg</td><td valign="top" align="center" rowspan="1" colspan="1">129.6&#x000b1;10.1</td><td valign="top" align="center" rowspan="1" colspan="1">126.3&#x000b1;11.1</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DBP, mm Hg</td><td valign="top" align="center" rowspan="1" colspan="1">80.7&#x000b1;6.6</td><td valign="top" align="center" rowspan="1" colspan="1">80.8&#x000b1;7.3</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Exercise, time/wk</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="4" colspan="1">NS<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;3</td><td valign="top" align="center" rowspan="1" colspan="1">15 (40.5)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (47.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;1&#x02013;3</td><td valign="top" align="center" rowspan="1" colspan="1">10 (27.0)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (15.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Never</td><td valign="top" align="center" rowspan="1" colspan="1">12 (32.4)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (36.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Current smoker</td><td valign="top" align="center" rowspan="1" colspan="1">10 (27.0)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (31.6)</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alcohol habits, time/wk</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="4" colspan="1">NS<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;3</td><td valign="top" align="center" rowspan="1" colspan="1">14 (37.8)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (44.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;3</td><td valign="top" align="center" rowspan="1" colspan="1">14 (37.8)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (28.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Never</td><td valign="top" align="center" rowspan="1" colspan="1">9 (24.3)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (26.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CHD family history</td><td valign="top" align="center" rowspan="1" colspan="1">9 (24.3)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (23.7)</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FPG, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">114.1&#x000b1;11.1</td><td valign="top" align="center" rowspan="1" colspan="1">116.5&#x000b1;14.9</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cholesterol, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">223.6&#x000b1;28.7</td><td valign="top" align="center" rowspan="1" colspan="1">215.5&#x000b1;26.5</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-C, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">49.2&#x000b1;9.6</td><td valign="top" align="center" rowspan="1" colspan="1">46.9&#x000b1;10.0</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL-C, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">144.7&#x000b1;19.8</td><td valign="top" align="center" rowspan="1" colspan="1">136.1&#x000b1;24.0</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-HDL-C, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">174.4&#x000b1;28.8</td><td valign="top" align="center" rowspan="1" colspan="1">168.6&#x000b1;24.4</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">162.4&#x000b1;50.6</td><td valign="top" align="center" rowspan="1" colspan="1">175.8&#x000b1;72.9</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">hs-CRP, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">0.15&#x000b1;0.16</td><td valign="top" align="center" rowspan="1" colspan="1">0.19&#x000b1;0.32</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HOMA-IR</td><td valign="top" align="center" rowspan="1" colspan="1">2.9&#x000b1;1.2</td><td valign="top" align="center" rowspan="1" colspan="1">3.5&#x000b1;1.7</td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>a</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are expressed as mean&#x000b1;SD or number (%).</p><p>LSM, life style modification; NS, not significant; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride; hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance.</p><p><sup>a</sup>The <italic>P</italic> values are computed from two-sample <italic>t</italic> test; <sup>b</sup>The <italic>P</italic> values are computed from v2-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Changes of Metabolic Parameters after 12 Months Intervention in Both Groups</title></caption><alternatives><graphic xlink:href="enm-31-120-i002"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="left" rowspan="2" colspan="1">Variable</th><th valign="middle" align="center" rowspan="1" colspan="3">Pitavastatin+LSM (<italic>n</italic>=37)</th><th valign="middle" align="center" rowspan="1" colspan="3">LSM only (n=38)</th><th valign="middle" align="center" rowspan="2" colspan="1"><italic>P</italic> value<sup>a</sup></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Baseline</th><th valign="middle" align="center" rowspan="1" colspan="1">12 months</th><th valign="middle" align="center" rowspan="1" colspan="1">Change</th><th valign="middle" align="center" rowspan="1" colspan="1">Baseline</th><th valign="middle" align="center" rowspan="1" colspan="1">12 months</th><th valign="middle" align="center" rowspan="1" colspan="1">Change</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">TC, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">223.6&#x000b1;28.7</td><td valign="top" align="center" rowspan="1" colspan="1">178.2&#x000b1;25.9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;45.4&#x000b1;34.7<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">215.7&#x000b1;26.8</td><td valign="top" align="center" rowspan="1" colspan="1">215.7&#x000b1;22.7</td><td valign="top" align="center" rowspan="1" colspan="1">0&#x000b1;22.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">162.4&#x000b1;50.6</td><td valign="top" align="center" rowspan="1" colspan="1">137.7&#x000b1;54.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;24.7&#x000b1;54.1<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">175.8&#x000b1;72.9</td><td valign="top" align="center" rowspan="1" colspan="1">179.6&#x000b1;106.6</td><td valign="top" align="center" rowspan="1" colspan="1">2.7&#x000b1;98.1</td><td valign="top" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-C, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">49.2&#x000b1;9.6</td><td valign="top" align="center" rowspan="1" colspan="1">49.9&#x000b1;9.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.7&#x000b1;6.2</td><td valign="top" align="center" rowspan="1" colspan="1">47.2&#x000b1;10.0</td><td valign="top" align="center" rowspan="1" colspan="1">49.2&#x000b1;8.5</td><td valign="top" align="center" rowspan="1" colspan="1">2.0&#x000b1;7.3</td><td valign="top" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL-C, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">144.7&#x000b1;19.8</td><td valign="top" align="center" rowspan="1" colspan="1">103.0&#x000b1;24.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;41.7&#x000b1;29.6<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">135.8&#x000b1;24.3</td><td valign="top" align="center" rowspan="1" colspan="1">134.1&#x000b1;22.3</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;1.7&#x000b1;23.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-HDL-C, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">174.4&#x000b1;28.8</td><td valign="top" align="center" rowspan="1" colspan="1">138.4&#x000b1;28.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;46.0&#x000b1;34.4<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">168.6&#x000b1;24.4</td><td valign="top" align="center" rowspan="1" colspan="1">166.5&#x000b1;22.8</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;2.0&#x000b1;21.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ApoB-100/A1 ratio</td><td valign="top" align="center" rowspan="1" colspan="1">0.75&#x000b1;0.17</td><td valign="top" align="center" rowspan="1" colspan="1">0.55&#x000b1;0.18</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;0.21&#x000b1;0.16<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.71&#x000b1;0.18</td><td valign="top" align="center" rowspan="1" colspan="1">0.66&#x000b1;0.13</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;0.05&#x000b1;0.12<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adiponectin, &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">2.40&#x000b1;0.997</td><td valign="top" align="center" rowspan="1" colspan="1">3.37&#x000b1;1.47</td><td valign="top" align="center" rowspan="1" colspan="1">0.965&#x000b1;1.38<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">3.15&#x000b1;1.87</td><td valign="top" align="center" rowspan="1" colspan="1">3.67&#x000b1;1.76</td><td valign="top" align="center" rowspan="1" colspan="1">0.519&#x000b1;1.14<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HMW-adiponectin, &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">2.20&#x000b1;1.30</td><td valign="top" align="center" rowspan="1" colspan="1">2.61&#x000b1;1.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.404&#x000b1;1.01<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">2.20&#x000b1;1.30</td><td valign="top" align="center" rowspan="1" colspan="1">3.06&#x000b1;2.77</td><td valign="top" align="center" rowspan="1" colspan="1">0.775&#x000b1;1.07<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ApoB-48, &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">5.64&#x000b1;1.55</td><td valign="top" align="center" rowspan="1" colspan="1">5.36&#x000b1;1.75</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;0.272&#x000b1;2.17</td><td valign="top" align="center" rowspan="1" colspan="1">5.98&#x000b1;3.20</td><td valign="top" align="center" rowspan="1" colspan="1">6.36&#x000b1;2.62</td><td valign="top" align="center" rowspan="1" colspan="1">0.382&#x000b1;4.05</td><td valign="top" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lp-PLA<sub>2</sub>, &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">1.20&#x000b1;0.262</td><td valign="top" align="center" rowspan="1" colspan="1">1.25&#x000b1;0.251</td><td valign="top" align="center" rowspan="1" colspan="1">0.048&#x000b1;0.225</td><td valign="top" align="center" rowspan="1" colspan="1">1.21&#x000b1;0.241</td><td valign="top" align="center" rowspan="1" colspan="1">1.33&#x000b1;0.316</td><td valign="top" align="center" rowspan="1" colspan="1">0.116&#x000b1;0.288<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are expressed as mean&#x000b1;SD.</p><p>LSM, life style modification; TC, total cholesterol; TG, triglyceride; NS, not significant; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ApoB-100, apolipoprotein B100; ApoA1, apolipoprotein A1; HMW, high molecular weight; Lp-PLA<sub>2</sub>, lipoprotein-associated phospholipase A<sub>2</sub>.</p><p><sup>a</sup>Comparison of the changes between the groups by two-sample <italic>t</italic> test; <sup>b</sup><italic>P</italic>&#x0003c;0.05 by paired <italic>t</italic> test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Changes from Baseline in the Levels of ApoB-48 and Lp-PLA<sub>2</sub> according to Their Baseline Values (i.e., Below and Above Median Values)</title></caption><alternatives><graphic xlink:href="enm-31-120-i003"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="left" rowspan="2" colspan="1">Variable</th><th valign="middle" align="center" rowspan="1" colspan="3">Pitavastatin+LSM (<italic>n</italic>=37)</th><th valign="middle" align="center" rowspan="1" colspan="3">LSM only (<italic>n</italic>=38)</th><th valign="middle" align="center" rowspan="2" colspan="1"><italic>P</italic> value<sup>a</sup></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Baseline</th><th valign="middle" align="center" rowspan="1" colspan="1">12 months</th><th valign="middle" align="center" rowspan="1" colspan="1">Change</th><th valign="middle" align="center" rowspan="1" colspan="1">Baseline</th><th valign="middle" align="center" rowspan="1" colspan="1">12 months</th><th valign="middle" align="center" rowspan="1" colspan="1">Change</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Below median, &#x000b5;g/mL</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;ApoB-48</td><td valign="middle" align="center" rowspan="1" colspan="1">4.54 (4.02&#x02013;4.89)</td><td valign="middle" align="center" rowspan="1" colspan="1">4.64 (3.83&#x02013;6.35)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.15 (&#x02013;0.65 to 2.09)</td><td valign="middle" align="center" rowspan="1" colspan="1">4.57 (4.11&#x02013;4.94)</td><td valign="middle" align="center" rowspan="1" colspan="1">5.46 (4.70&#x02013;6.11)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.68 (0.21&#x02013;1.70)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.234</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Lp-PLA<sub>2</sub></td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (0.86&#x02013;1.17)</td><td valign="top" align="center" rowspan="1" colspan="1">1.12 (0.94&#x02013;1.38)</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 (0.00&#x02013;0.30)</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (0.91&#x02013;1.11)</td><td valign="top" align="center" rowspan="1" colspan="1">1.22 (1.14&#x02013;1.30)</td><td valign="top" align="center" rowspan="1" colspan="1">0.19 (0.10&#x02013;0.33)</td><td valign="top" align="left" rowspan="1" colspan="1">0.331</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Above median, &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1"/><td valign="bottom" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;ApoB-48</td><td valign="top" align="center" rowspan="1" colspan="1">6.09 (5.62&#x02013;7.30)</td><td valign="bottom" align="center" rowspan="1" colspan="1">5.07 (4.67&#x02013;5.75)</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#x02013;0.88 (&#x02013;2.51 to &#x02013;0.65)<sup>b</sup></td><td valign="bottom" align="center" rowspan="1" colspan="1">6.41 (5.64&#x02013;7.70)</td><td valign="bottom" align="center" rowspan="1" colspan="1">5.99 (5.11&#x02013;6.63)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.14 (&#x02013;1.69 to 0.67)</td><td valign="bottom" align="left" rowspan="1" colspan="1">0.045<sup>b</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Lp-PLA<sub>2</sub></td><td valign="top" align="center" rowspan="1" colspan="1">1.44 (1.27&#x02013;1.48)</td><td valign="top" align="center" rowspan="1" colspan="1">1.40 (1.27&#x02013;1.56)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;0.03 (&#x02013;0.15 to 0.11)</td><td valign="top" align="center" rowspan="1" colspan="1">1.34 (1.29&#x02013;1.44)</td><td valign="top" align="center" rowspan="1" colspan="1">1.44 (1.15&#x02013;1.54)</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 (&#x02013;0.18 to 0.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.598</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are expressed as median (interquartile range). The values corresonding to the median of baseline apoB-48 and Lp-PLA<sub>2</sub> are 5.42 and 1.23 &#x000b5;g/mL, respectively.</p><p>ApoB-48, apolipoprotein B48; Lp-PLA<sub>2</sub>, lipoprotein-associated phospholipase A<sub>2</sub>; LSM, life style modification.</p><p><sup>a</sup>Comparison of the changes between the groups by Mann-Whitney <italic>U</italic> test; <sup>b</sup><italic>P</italic>&#x0003c;0.05 by Wilcoxon signed rank test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>